T7 Peptide TFA  (Synonyms: Tumstatin (74-98), human TFA)

T7 Peptide TFA is a protein synthesis inhibitor and anti-angiogenic agent, with a K_d of 10 nM for human transferrin receptor. T7 Peptide TFA inhibits the phosphorylation of focal adhesion kinase, the activation of phosphatidylinositol 3-kinase and Akt, the kinase activity of mTOR, as well as the phosphorylation of 4E-BP1 in endothelial cells. T7 Peptide TFA induces G0/G1 cell cycle arrest, apoptosis and protective autophagy in hepatocellular carcinoma cells, and suppresses tumor growth in mouse models. T7 Peptide TFA is applicable to research related to cancer, glioblastoma, hepatocellular carcinoma and glioma^[1][2][3][4].

T7 peptide TFA (4.5 μM; 21 h) specifically inhibits cap-dependent translation in C-PAE cells without affecting cap-independent translation^[1].
T7 peptide (4.5 μM) inhibits total protein synthesis in MLEC-wt cells^[1].
T7 peptide TFA (4.5 μM) does not inhibit total protein synthesis in MLEC-β3 null cells, indicating dependence on αVβ3 integrin for this activity^[1].
T7 peptide TFA (4.5 μM) does not inhibit total protein synthesis in MEF-wt cells, indicating αVβ3 integrin expression is essential but not sufficient for this activity^[1].
T7 peptide TFA (4.5 μM) does not inhibit total protein synthesis in non-endothelial cell lines, demonstrating endothelial cell specificity for this activity^[1].
The T7 peptide TFA (0.25-2 μM; 6-24 h) significantly reduces viability of Huh-7 and Hep3B human HCC cells in a concentration- and time-dependent manner, but has minimal effect on normal human liver L-02 cells^[3].
The T7 peptide TFA (0.25-1 μM; 24 h) induces significant apoptosis (both early and late) in Huh-7 and Hep3B human HCC cells^[3].
The T7 peptide TFA (0.25-1 μM; 24 h) induces G0/G1 cell cycle arrest in Huh-7 and Hep3B human HCC cells^[3].
The T7 peptide TFA (0.5-1 μM; 24 h) upregulates pro-apoptotic Bax, Fas, and FasL and downregulates anti-apoptotic Bcl-2 in a concentration-dependent manner in Huh-7 and Hep3B human HCC cells^[3].
The T7 peptide TFA (0.5-1 μM; 24 h) induces autophagy in Huh-7 and Hep3B human HCC cells by upregulating Beclin-1, Atg5, and LC3-II in a concentration-dependent manner^[3].
The T7 peptide TFA (1 μM; 24 h) has enhanced apoptotic effect in Huh-7 and Hep3B human HCC cells when autophagy is inhibited^[3].
The T7 peptide TFA (0.5-1 μM; 24 h) induces autophagy in Huh-7 and Hep3B human HCC cells via inhibition of the Akt/mTOR signaling pathway, and co-treatment with Akt/mTOR inhibitors enhances this autophagic response^[3].
T7 peptide (5 μM; 2 h at 37 °C) modified LDL shows enhanced cellular uptake in bEnd.3 and C6 cells via synergistic mediation by TfR and LDLR^[4].
T7 peptide TFA (0.5-6% molar ratio; 4 h at 37 °C) modification enhances BBB penetration and subsequent C6 glioma cell uptake, with optimal efficacy observed at a 4% molar ratio of T7 to LDL^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

T7 peptide TFA (2.5-5 mg/kg; i.p.; every other day) dose-dependently suppresses Hep3B xenograft tumor growth in nude mice, achieving a ~27% tumor cell apoptotic rate at the 5 mg/kg dose via pathways involving reduced Akt/mTOR phosphorylation, increased Bax expression, and decreased Bcl-2 expression^[3].
T7 peptide TFA (4% molar ratio; 0.5 mg/kg; intravenous tail vein injection) conjugation to LDL particles enhances accumulation in intracranial glioma tissue in female ICR mice bearing C6 glioma^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3018.36 (free base)

C₁₃₇H₁₈₉N₃₃O₃₉S₃.xC₂HF₃O₂

Solid

White to off-white

Thr-Met-Pro-Phe-Leu-Phe-Cys-Asn-Val-Asn-Asp-Val-Cys-Asn-Phe-Ala-Ser-Arg-Asn-Asp-Tyr-Ser-Tyr-Trp-Leu (Disulfide bridge: Cys7-Cys13)

TMPFLFCNVNDVCNFASRNDYSYWL (Disulfide bridge: Cys7-Cys13)

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. Maeshima Y, et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science. 2002 Jan 4;295(5552):140-3.  [Content Brief]

  [2]. Liang M, et al. Enhanced blood-brain barrier penetration and glioma therapy mediated by T7 peptide-modified low-density lipoprotein particles. Drug Deliv. 2018;25(1):1652-1663.  [Content Brief]

  [3]. Liu F, et al. T7 peptide cytotoxicity in human hepatocellular carcinoma cells is mediated by suppression of autophagy. Int J Mol Med. 2019;44(2):523-534.  [Content Brief]

  [4]. Kim G, et al. Systemic delivery of microRNA-21 antisense oligonucleotides to the brain using T7-peptide decorated exosomes. J Control Release. 2020;317:273-281.  [Content Brief]